8-K: Solsence Reports Record First Quarter 2025 Revenue, Up 48%

Solsence, Inc. announced record first quarter 2025 revenue of $14.6 million, a 48% increase compared to the same period in 2024, driven by strong sales across its consumer product suite.

Summary

• Solsence, Inc. reported a 48% increase in revenue for the first quarter of 2025, reaching a record $14.6 million.
• This growth was primarily driven by strong sales of consumer products and a new product line with a key brand partner.
• Gross profit for the quarter was $3.3 million, with a gross margin of 23%, down from 36% in the same period last year due to one-time start-up costs.
• Net income for the first quarter was breakeven, compared to a net income of $0.9 million in the first quarter of 2024.
• The company uplisted to Nasdaq under the ticker SLSN, aiming to increase visibility and access to capital markets.
• Solsence anticipates continued sequential revenue growth based on shipped and open orders exceeding $45 million.
• The company secured new patents for its Kleair technology in Japan, a plant-based antioxidant technology in South Korea, and a skin health technology in Mexico.

Sentiment

Score: 7

Explanation: The document expresses optimism about future growth and the benefits of the Nasdaq uplisting, but acknowledges the negative impact of one-time costs on current profitability. The overall tone is positive but tempered by the financial results.

Positives

• Record revenue of $14.6 million, a 48% increase year-over-year.
• Significant increase in shipment and production volumes.
• Successful uplisting to Nasdaq, enhancing visibility and access to capital.
• Expansion of intellectual property portfolio with new patents.
• Strong relationships with key customers and new brand partners.
• Anticipated rebound in gross margins in the second quarter.

Negatives

• Gross margin decreased to 23% due to one-time start-up costs.
• Net income was breakeven, compared to $0.9 million in the same period last year.
• Start-up issues related to a new product launch impacted profitability in the first quarter.

Risks

• Dependence on a limited number of key customers.
• Uncertain demand for and acceptance of the company's products.
• Potential impact of tariffs on costs and supply chain.
• Impact of competitive products and technologies.
• The ability of the Company to maintain an appropriate electronic trading venue.
• Potential disruption in commercial activities occasioned by public health issues, terrorist activity and armed conflict.

Future Outlook

Solsence anticipates continued sequential revenue growth based on current shipped and open orders that are in excess of $45 million and expects a rebound in gross margins starting in the second quarter of 2025.

Management Comments

• We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products, said Jess Jankowski, President and Chief Executive Officer of Solsence.
• We believe that this new brand partner will drive significant growth in the future fueled by demand for our exceptional products and our collaborative efforts, said Kevin Cureton, Chief Operating Officer.
• Building on our positive momentum, Solsence rebrand and Nasdaq uplisting, we look forward to capitalizing on the significant opportunities ahead to drive long-term shareholder value, said Mr. Jankowski.

Industry Context

Solsence operates in the competitive beauty and life science categories, serving as a CDMO for various brands. The company's focus on innovation, patent-protected formulations, and strategic partnerships positions it to capture market share in the growing global beauty market.

Comparison to Industry Standards

• Solsence's revenue growth of 48% significantly outpaces the average growth rate for the global beauty market, which is typically in the single digits.
• Compared to other CDMOs, Solsence differentiates itself through its proprietary technology and vertically integrated operations, enabling faster product development and market entry for its brand partners.
• The company's focus on patent protection and innovation aligns with industry trends towards scientifically-driven and high-performance beauty solutions.
• Solsence's key customers include Colorescience, Tatcha, and Credo, which are well-regarded brands in the beauty industry, indicating the company's ability to attract and retain top-tier clients.

Stakeholder Impact

• Shareholders can expect increased visibility and potential for long-term value creation due to the Nasdaq uplisting.
• Employees may benefit from the company's growth and expansion.
• Customers can anticipate continued innovation and high-performance products.
• Suppliers may experience increased demand for raw materials and packaging components.
• Creditors may see improved financial stability and creditworthiness.

Next Steps

• Scale operations for future gross margin expansion.
• Continue to strengthen relationships with key customers and brand partners.
• Announce the appointment of a dedicated CFO.
• Monitor the impact of tariffs and macroeconomic conditions.
• Focus on reducing controllable variable product manufacturing costs.

Key Dates

Keywords

Solsence, revenue, CDMO, Nasdaq, patents, beauty, skincare, manufacturing, financial results